HAMBURG, Germany , Aug. 3, 2022 /PRNewswire/ -- Vela Diagnostics has announced its appointment by the National Public Health Laboratory of Kenya (NPHL) as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund.
The NPHL operates under Kenya's Ministry of Health and plays an important role in the nation's healthcare by providing reference testing for key diseases and in response to disease outbreaks. It is currently embarking on a program to trace and curb spread of COVID-19 in Kenya , an effort funded by The Global Fund.
The Global Fund is an international financing and partnership organization that aims to attract, leverage and invest additional resources for prevention, treatment and care programs of diseases such as AIDS, TB and malaria.
Vela Diagnostics has an extensive infectious diseases portfolio, with solutions to support COVID-19 testing. These include the ViroKey® SARS-CoV-2 RT-PCR Test v2.0, a test for the diagnosis of SARS-CoV-2 infections, and the ViroKey SARS-CoV-2 ID RT-PCR Test, which quickly identifies specific strains and potential variants of concern.
Especially relevant to the Kenyan NPHL's surveillance efforts is the ViroKey SQ FLEX SARS-CoV-2 Genotyping Assay, a next-generation sequencing (NGS)-based test for detecting genomic mutations of the SARS-CoV-2 RNA genome from nasopharyngeal or oropharyngeal swabs. The accompanying reporter software automatically calls out mutations and classifies them by lineage, providing critical insights to the molecular epidemiology of SARS-CoV-2 infections.
Dr Leonard Kingwara , Head of the Genomics and Molecular Surveillance Laboratory Unit in Kenya , attests to the efficiency of Vela Diagnostics' SARS-CoV-2 genotyping assay in results generation, as well as its utility for expanding the scope of pathogen public health surveillance. "Vela Diagnostics' genotyping assay ensures timely results through automation and reduction of hands-on procedures. This has facilitated timely result releases for various research projects," says Dr Kingwara.
"We are very excited to be appointed as the primary supplier for genotyping kits for the Kenyan NPHL," says Dr Andreas Goertz , Managing Director of Vela Diagnostics EMEA. "This grants us an invaluable opportunity to expand our presence in Africa , including South Africa where our HIV genotyping assay is currently undergoing registration for sales in the country."
The Sentosa® SQ HIV-1 Genotyping Kit is a US FDA De Novo designated NGS assay for detecting HIV-1 drug resistance mutations (DRMs). "Our HIV-1 genotyping solution is the only commercially available NGS solution authorized by the FDA for sale in the US, and can detect down to 5% mutation frequency; more sensitive than traditional Sanger sequencing-based platforms. It also detects for mutations in the three most common drug target regions in one test, providing comprehensive mutation profiles for clinicians to decide on the optimal antiretroviral therapy to prescribe," says Rachel Yap , Global Product Manager for Vela Diagnostics.
"We believe our HIV-1 genotyping assay can act as a key tool in global efforts to curb the HIV pandemic and help achieve the goal of '90-90-90'," says Sam Dajani , CEO and Chairman of the Board for Vela Diagnostics, referring to the "90-90-90" treatment target originally created by the Joint United Nations Programme on HIV/AIDS (UNAIDS). It calls for 90% of HIV-infected individuals to be diagnosed by 2030, 90% of whom will be on antiretroviral therapy and 90% of whom will have achieved sustained virologic suppression.
Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA's test solutions utilize the automated Sentosa platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
All Sentosa products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
When Pip Petersen heard the name of his team announced as the winner of Gilead’s Hacks for HIV Prevention contest, his jaw dropped open in surprise. Pip, a PhD student in physics at Case Western Re...
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
In the recall expansion, “botulism” has been mentioned.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Joining me on the call today are Sujal Shah, chief executive officer; Chuck McWherter, chief scientific officer; Dennis Kim, chief medical officer; Lewis Stuart, chief commercial officer; and Dan Menold, VP, finance. Following our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated time lines and data release date, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
Vedanta, a microbiome startup that raised $68 million just over a year ago is letting about 20% of its staff go.
The Supreme Court decision to overturn Roe v Wade triggered a wave of outrage from pro-choice groups as states moved quickly to criminalize abortion. Now, investors are taking action with their dollars, deploying capital to support women’s health startups.
With CDC relaxing COVID-19 guidelines, you can still shop KN95 face masks for better protection—shop face masks from Amazon, Maskc, Vida and more.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
The latest guidance aligns with the recommendations set for those who are up to date on their COVID-19 vaccines
As Americans shake off pandemic trends and return to the gym, fitness chains like Planet Fitness (PLNT) are seeing increased membership sign-ups — particularly from one demographic.
We still have a chance to contain the monkeypox outbreak, but experts fear the virus could become endemic in the U.S.